Live Breaking News & Updates on Esperion Therapeutics Inc
Stay updated with breaking news from Esperion therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) and Clearmind Medicine (NASDAQ:CMND – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk. Profitability This table compares Esperion Therapeutics and […] ....
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) and Clearmind Medicine (NASDAQ:CMND – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a summary of […] ....
HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report issued on Tuesday, Benzinga reports. They currently have a $16.00 target price on the biopharmaceutical company’s stock. A number of other equities analysts also recently commented on the company. StockNews.com downgraded Esperion Therapeutics from a strong-buy rating […] ....
Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has been assigned a consensus rating of “Hold” from the five research firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price […] ....